Core Viewpoint - Nasus Pharma is set to present data on its investigational intranasal epinephrine powder formulation, NS002, at the AAAAI 2026 Annual Meeting, highlighting its potential for superior absorption and stability compared to traditional liquid formulations [1][2]. Group 1: Product Development - NS002 is designed as a needle-free intranasal powder aimed at delivering epinephrine rapidly in emergency situations, particularly for anaphylaxis treatment [2][4]. - The product utilizes proprietary powder-based intranasal (PBI) technology, which leverages the nasal cavity's vascular network for quick absorption, potentially offering faster and higher absorption rates than liquid-based nasal products [4]. Group 2: Presentation Details - The presentation titled "Nasal epinephrine spray for anaphylaxis: which is better - powder or liquid?" will showcase that nasal powder has significantly higher deposition in the nasal cavity compared to liquid nasal spray, which could enhance blood absorption [3]. - Another presentation will focus on the stability of FMXIN002 Epinephrine Intranasal Powder Spray throughout three freeze-thaw cycles, indicating its robustness [3]. Group 3: Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products for acute medical conditions, with NS002 being a key candidate for anaphylaxis treatment [4].